ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free

A development code.

Its studies are mostly in Hyperemia, led by Alcon.

Furthest: phase 3, since Apr 9, 20262 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alcon22 open or runningphase 3since Apr 9, 2026Apr 9, 2026Nov 2026phase 3 · NCT07578363

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 9, 2026First study: phase 3 study in Ocular HyperemiaFirst studyNCT07531043 · 230 planned · United States
  2. May 5, 2026Phase 3 study in Ocular HyperemiaNCT07578363 · 178 planned · United States

Ahead

  1. Nov 2026Primary completion: phase 3 study in Ocular HyperemiaNCT07578363
  2. Feb 2027Primary completion: phase 3 study in Ocular HyperemiaNCT07531043

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07578363Ocular Hyperemia · United States3RecruitingNov 2026178
NCT07531043Ocular Hyperemia · United States3RecruitingFeb 2027230

How it is read

Names in the registry

  • “Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free”, 2 entries

Codes read as this program: FID123472.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.